Puma Biotechnology (PBYI) Non Operating Income (2011 - 2026)
Puma Biotechnology (PBYI) posted Non Operating Income of $401000.0 for Q1 2026, up 40000.0% on a QoQ basis from $1000.0 in Q4 2025, and up 155.93% year-over-year from $156685.0 in Q1 2025.
Puma Biotechnology (PBYI) Non Operating Income (2011 - 2026) Analysis & Trends
Puma Biotechnology's Non Operating Income history runs 16 years deep, the most recent figure standing at $401000.0 for Q1 2026.
- Quarterly Non Operating Income rose 155.93% year-over-year to $401000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$399000.0 (up 92.45% YoY) and the FY2025 annual result came in at -$1.5 million, up 77.91% from the prior year.
- Non Operating Income was $401000.0 for Q1 2026 at Puma Biotechnology, up from $1000.0 in the prior quarter.
- Across five years, Non Operating Income topped out at $401000.0 in Q1 2026 and bottomed at -$15.3 million in Q4 2022.
- A 5-year average of -$2.4 million and a median of -$2.0 million in 2023 frame the typical range for Non Operating Income.
- Annual changes were most pronounced in 2022 — Non Operating Income slumped 539.73% — and 2026, when it jumped 155.93%.
- Puma Biotechnology's Non Operating Income stood at -$15.3 million in 2022, then soared by 86.99% to -$2.0 million in 2023, then soared by 43.48% to -$1.1 million in 2024, then surged by 100.09% to $1000.0 in 2025, then surged by 40000.0% to $401000.0 in 2026.
- Business Quant data shows PBYI's Non Operating Income at $401000.0 in Q1 2026, $1000.0 in Q4 2025, and -$330000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -9.22 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 444,000.00 |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 188.30 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | 5.75 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -8.59 Mn |
| 10 | Puma Biotechnology | 406.51 Mn | 368.22 Mn | 34.39 Mn | 401,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 401,000.00 |
| Dec 31, 2025 | 1,000.00 |
| Sep 30, 2025 | -330,000.00 |
| Jun 30, 2025 | -471,000.00 |
| Mar 31, 2025 | -717,000.00 |
| Dec 31, 2024 | -1.13 Mn |
| Sep 30, 2024 | -1.47 Mn |
| Jun 30, 2024 | -1.97 Mn |
| Mar 31, 2024 | -2.30 Mn |
| Dec 31, 2023 | -1.99 Mn |
| Sep 30, 2023 | -2.58 Mn |
| Jun 30, 2023 | -2.58 Mn |
| Mar 31, 2023 | -2.82 Mn |
| Dec 31, 2022 | -15.33 Mn |
| Sep 30, 2022 | -2.69 Mn |
| Jun 30, 2022 | -2.63 Mn |
| Mar 31, 2022 | -2.62 Mn |
| Dec 31, 2021 | -2.40 Mn |
| Sep 30, 2021 | -35.68 Mn |
| Jun 30, 2021 | 11.57 Mn |